Blinatumomab which targets CD19 on cells of B-lineage origin and CD3 on T cells was the first BsAb approved by the US Food and Drug Administration (FDA) for adult and pediatric patients with B cell precursor acute lymphoblastic leukemia (ALL) [27]. Here, CD19 is linked to acute lymphoblastic leukemia.